SG11202104307VA - Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha - Google Patents

Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha

Info

Publication number
SG11202104307VA
SG11202104307VA SG11202104307VA SG11202104307VA SG11202104307VA SG 11202104307V A SG11202104307V A SG 11202104307VA SG 11202104307V A SG11202104307V A SG 11202104307VA SG 11202104307V A SG11202104307V A SG 11202104307VA SG 11202104307V A SG11202104307V A SG 11202104307VA
Authority
SG
Singapore
Prior art keywords
ifn
amide
alpha
modulation
treatment
Prior art date
Application number
SG11202104307VA
Other languages
English (en)
Inventor
Steven H Spergel
William J Pitts
Michael E Mertzman
Ryan M Moslin
Trevor C Sherwood
John L Gilmore
Alaric J Dyckman
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11202104307VA publication Critical patent/SG11202104307VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202104307VA 2018-10-30 2019-10-28 Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha SG11202104307VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752414P 2018-10-30 2018-10-30
PCT/US2019/058268 WO2020092196A1 (en) 2018-10-30 2019-10-28 Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha

Publications (1)

Publication Number Publication Date
SG11202104307VA true SG11202104307VA (en) 2021-05-28

Family

ID=68582450

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104307VA SG11202104307VA (en) 2018-10-30 2019-10-28 Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha

Country Status (13)

Country Link
US (1) US12240840B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873892A1 (cg-RX-API-DMAC7.html)
JP (1) JP7489381B2 (cg-RX-API-DMAC7.html)
KR (1) KR102858043B1 (cg-RX-API-DMAC7.html)
CN (1) CN113227071B (cg-RX-API-DMAC7.html)
AU (1) AU2019373203B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007861A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118094A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191142A1 (cg-RX-API-DMAC7.html)
IL (1) IL282840B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021004562A (cg-RX-API-DMAC7.html)
SG (1) SG11202104307VA (cg-RX-API-DMAC7.html)
WO (1) WO2020092196A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021195360A1 (en) * 2020-03-27 2021-09-30 Landos Biopharma, Inc. Plxdc2 ligands
KR20230004771A (ko) 2020-04-28 2023-01-06 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
CN113773262B (zh) * 2020-06-09 2024-08-09 江苏先声药业有限公司 哒嗪类化合物
CN114057651B (zh) * 2020-07-31 2025-05-27 正大天晴药业集团股份有限公司 含酰胺基的tyk2抑制剂化合物
CN116547276A (zh) * 2020-12-08 2023-08-04 正大天晴药业集团股份有限公司 含酰胺基和杂环烷基的tyk2抑制剂化合物
CN122520625A (zh) 2020-12-22 2026-08-07 益方生物科技(上海)股份有限公司 杂芳基化合物及其制备方法和用途
CN114907326B (zh) * 2021-02-06 2025-02-18 正大天晴药业集团股份有限公司 含酰胺基和联环的tyk2抑制剂化合物
TWI925948B (zh) * 2021-02-06 2026-05-21 大陸商正大天晴藥業集團股份有限公司 含聯環的tyk2抑制劑化合物、藥物組合物及其用途
EP4308556A4 (en) * 2021-03-16 2025-02-19 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
KR20240007242A (ko) * 2021-05-14 2024-01-16 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
US20240317718A1 (en) * 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
KR20240008338A (ko) * 2021-05-14 2024-01-18 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
WO2022253333A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 酰胺类化合物及其应用
CN115466289B (zh) * 2021-06-11 2026-07-03 爱科诺生物医药(苏州)有限公司 具有tyk2抑制活性的化合物,包含其的药物组合物,及其应用
CA3223641A1 (en) * 2021-06-22 2022-12-29 Wenyuan Qian Sulfoximine compound and use thereof
CN117794911A (zh) * 2021-07-15 2024-03-29 南京明德新药研发有限公司 含硫/磷的芳基类化合物及其应用
WO2023027948A1 (en) * 2021-08-21 2023-03-02 Relay Therapeutics, Inc. Jak2 inhibitors and methods of use thereof
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
TW202339749A (zh) 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Tyk2抑制劑及其組合物和方法
CN116283928A (zh) * 2021-12-20 2023-06-23 艾立康药业股份有限公司 一种哒嗪类化合物、其制备方法和应用
WO2023213308A1 (zh) * 2022-05-05 2023-11-09 苏州隆博泰药业有限公司 酰胺取代的杂环化合物及其医药用途
CN117263913A (zh) 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 杂芳基化合物、固体形式、制备方法及其用途
JP2025523848A (ja) * 2022-07-14 2025-07-25 バイオジェン・エムエイ・インコーポレイテッド チロシンキナーゼ2阻害剤及びその使用
WO2024044486A1 (en) * 2022-08-22 2024-02-29 Ajax Therapeutics, Inc. Jak2 inhibitor compounds
CN120152968A (zh) * 2022-11-08 2025-06-13 百时美施贵宝公司 取代的杂环化合物
JP2025539787A (ja) * 2022-11-16 2025-12-09 ヴァーンウィ セラピューティクス,インコーポレイテッド Tyk2阻害剤
AU2023412260A1 (en) * 2022-12-22 2025-05-29 Usynova Pharmaceuticals Ltd. Salt form and crystal form of pyridine multi-substituted compound and preparation method therefor
WO2024174229A1 (en) * 2023-02-24 2024-08-29 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Covalent binding compounds and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922841B8 (en) * 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HRP20220766T1 (hr) * 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
AR094537A1 (es) * 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
JP7485609B2 (ja) * 2018-03-22 2024-05-16 ブリストル-マイヤーズ スクイブ カンパニー IL-12、IL-23および/またはIFNα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物
PE20250262A1 (es) * 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos

Also Published As

Publication number Publication date
AU2019373203B2 (en) 2024-10-24
BR112021007861A2 (pt) 2021-08-03
US20230020273A1 (en) 2023-01-19
IL282840B2 (en) 2025-03-01
CN113227071B (zh) 2024-06-25
IL282840B1 (en) 2024-11-01
US12240840B2 (en) 2025-03-04
KR102858043B1 (ko) 2025-09-10
EA202191142A1 (ru) 2021-07-20
WO2020092196A1 (en) 2020-05-07
CN113227071A (zh) 2021-08-06
MX2021004562A (es) 2021-06-15
EP3873892A1 (en) 2021-09-08
IL282840A (en) 2021-06-30
CA3118094A1 (en) 2020-05-07
KR20210086674A (ko) 2021-07-08
JP7489381B2 (ja) 2024-05-23
JP2022506445A (ja) 2022-01-17
AU2019373203A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
IL282840A (en) Substituted amide heterocyclic compounds for the treatment of conditions involving the regulation of IL-12, IL-23 AND/OR IFN-ALPHA
IL281277A (en) Preparations and methods for treating viral infections
IL269599A (en) 11,13-modified saxitoxins for the treatment of pain
SG11202103033WA (en) Compositions and methods for the treatment of presbyopia
ZA202006610B (en) Compositions for the treatment of skin conditions
HUE057426T2 (hu) Heteroaril-szubsztituált béta-hidroxietilamin-származékok magas vécukorszint kezelésére való alkalmazásra
IL272121A (en) Preparation and methods for the treatment of myopia
IL276363A (en) Combination of Sting agonist and IL-15/IL15-RA for cancer treatment
GB201820450D0 (en) Compound and its use for the treatment of alpha1-antitryspin deficiency
ZA202007055B (en) Compositions for the treatment of skin conditions
IL276482A (en) Compounds for pain management
ZA202007320B (en) Compounds for pain treatment, compositions comprising same, and methods of using same
IL280218A (en) Methods for the treatment of HFPEF using dapagliflozin and compounds containing it
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
SG11202100269VA (en) Compounds for use in the treatment of fascioliasis
IL276228A (en) Compounds and preparations for the treatment of pain
IL281512A (en) Use of gboxdol to treat Tourette's syndrome, tics and stuttering
IL280262A (en) Compositions and methods for treating cancer
PL3810625T3 (pl) Sposoby i kompozycje do leczenia zakażenia wirusem zapalenia wątroby typu b
PL3618806T3 (pl) Kompozycja do leczenia aft i owrzodzeń jamy ustnej
SG11202105591UA (en) Substance for treatment or prevention of diseases, method for designing the same, and method for preparing the same
SG11202105593QA (en) Substance for treatment or prevention of diseases, method for designing the same, and method for preparing the same
IL278984A (en) Spinamide for the treatment of muscle deformity
GB2574944B (en) Methods and compositions for the treatment of pain and/or inflammation
GB201820452D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency